Comments Sought on Collecting Postmarket Race Data
12/08/2003
Federal Register Notice: FDA is requesting comment on the advantages and disadvantages of systematically collecting race and ethnicity data in postmarketing adverse event reports. FDA is also seeking feedback on whether FDA's MedWatch forms (Forms 3500 and 3500A) should be amended to collect the race and ethnicity data. Comments should be submitted by 2/6/04. To view this notice, click here.
